Ellipta

Ellipta is a line of dry-powder inhalers developed and marketed by GlaxoSmithKline (GSK) for delivering inhaled medications to treat asthma and chronic obstructive pulmonary disease (COPD). The Ellipta devices are designed to provide simple, once-daily dosing with minimal coordination, using a disposable inhaler that loads a dose when the protective cover is opened and the patient inhales through the mouthpiece. Each device includes a dose counter to help users track remaining inhalations.

Several medicines are dispensed with the Ellipta device, including Breo Ellipta (fluticasone furoate/vilanterol), Arnuity Ellipta (fluticasone furoate), Anoro Ellipta (umeclidinium/vilanterol), and Incruse Ellipta (umeclidinium). These products differ in active ingredients and approved indications but share the common Ellipta device technology. Most are intended for maintenance therapy and are taken once daily; they are not rescue medications for acute symptoms.

Indications generally cover maintenance treatment of asthma or COPD in adults and, for some products, in certain pediatric patients, under medical supervision. All Ellipta-based therapies are prescription medications and should be used exactly as prescribed.

History and status: The Ellipta inhaler line was introduced in the early 2010s as part of GSK’s expanding portfolio of inhaled therapies. The devices are designed to be easy to use and to provide clear dose counting, supporting adherence and routine maintenance therapy in appropriate patients.